Alpine Global Management’s VBI Vaccines, Inc. New Common Stock (Canada) VBIV Stock Holding History

Alpine Global Management’s Portfolio VBIV Stock Details VBIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-25,000	Closed	-$15.1K	–	537
2024 Q1	$15.1K	Hold	25,000	–	–	﹤0.01%	192
2023 Q4	$14.7K	Hold	25,000	–	–	﹤0.01%	182
2023 Q3	$16.7K	Buy	+25,000	New	+$30.6K	﹤0.01%	148
2022 Q1	–	Sell	-1,842	Closed	-$129K	–	763
2021 Q4	$129K	Buy	+1,842	New	+$155K	0.02%	567
2021 Q3	–	Sell	-483	Closed	-$49K	–	388
2021 Q2	$49K	Buy	+483	New	+$47.1K	0.01%	282
2018 Q3	–	Sell	-2,686	Closed	-$222K	–	101
2018 Q2	$222K	Buy	+2,686	New	+$259K	0.11%	53

Other funds holding VBIV

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Alpine Global Management's VBIV Position: Q2 2024 in Review

Alpine Global Management sold out of VBI Vaccines, Inc. New Common Stock (Canada) (VBIV) in Q2 2024, closing a stake of 25,000 shares — an estimated $15.1K sold.

Alpine Global Management first reported a position in VBIV in Q2 2018 and held it in 6 quarters. The position peaked at $222K in Q2 2018. 41 funds tracked by Wall St. Rank hold VBIV as of Q2 2024.

Alpine Global Management reported no remaining VBI Vaccines, Inc. New Common Stock (Canada) position as of Q2 2024 after selling out during the quarter.
Alpine Global Management sold 25,000 VBI Vaccines, Inc. New Common Stock (Canada) shares in Q2 2024, an estimated $15.1K.
Alpine Global Management first reported a position in VBI Vaccines, Inc. New Common Stock (Canada) in Q2 2018 and held it in 6 quarters.
Alpine Global Management's VBI Vaccines, Inc. New Common Stock (Canada) position peaked at $222K in Q2 2018.
41 funds tracked by Wall St. Rank held VBI Vaccines, Inc. New Common Stock (Canada) as of Q2 2024.

Based on Alpine Global Management's 13F filing for Q2 2024, filed 14 Aug 2024.